| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
18,792 |
16,277 |
$2.72M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
9,938 |
8,266 |
$1.04M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,923 |
4,981 |
$547K |
| 71045 |
Radiologic examination, chest; single view |
1,947 |
1,683 |
$292K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,234 |
1,017 |
$201K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
321 |
271 |
$147K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,059 |
2,474 |
$126K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,261 |
1,770 |
$114K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,417 |
1,218 |
$102K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,918 |
1,706 |
$89K |
| 80053 |
Comprehensive metabolic panel |
11,267 |
9,411 |
$69K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
12,644 |
10,492 |
$57K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
536 |
502 |
$49K |
| 70450 |
Computed tomography, head or brain; without contrast material |
252 |
204 |
$25K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
145 |
116 |
$25K |
| 87449 |
|
1,364 |
592 |
$10K |
| 84484 |
|
1,221 |
1,020 |
$9K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
49 |
37 |
$6K |
| 83690 |
|
1,271 |
1,064 |
$5K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,152 |
880 |
$5K |
| 84443 |
Thyroid stimulating hormone (TSH) |
534 |
451 |
$3K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
72 |
67 |
$3K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
156 |
143 |
$2K |
| 81001 |
|
1,447 |
1,251 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
1,611 |
1,303 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
438 |
387 |
$2K |
| 80061 |
Lipid panel |
321 |
282 |
$2K |
| 83880 |
|
111 |
89 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
36 |
27 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
309 |
265 |
$2K |
| 81025 |
|
222 |
195 |
$2K |
| 84439 |
|
428 |
352 |
$1K |
| 80305 |
|
163 |
139 |
$1K |
| 82746 |
|
209 |
183 |
$1K |
| 82728 |
|
190 |
171 |
$954.12 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
120 |
114 |
$721.52 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
105 |
61 |
$680.33 |
| 83550 |
|
189 |
171 |
$602.69 |
| 82977 |
|
289 |
229 |
$598.25 |
| 84703 |
|
108 |
89 |
$597.90 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
14 |
12 |
$591.24 |
| 81003 |
|
415 |
355 |
$569.11 |
| 86140 |
|
164 |
152 |
$553.35 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
20 |
12 |
$539.84 |
| 83540 |
|
189 |
171 |
$446.42 |
| 71046 |
Radiologic examination, chest; 2 views |
13 |
12 |
$407.19 |
| 82150 |
|
110 |
94 |
$380.38 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
71 |
61 |
$350.55 |
| 83735 |
|
113 |
97 |
$289.98 |
| 85652 |
|
135 |
127 |
$250.62 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
53 |
51 |
$182.54 |
| 85379 |
|
12 |
12 |
$92.99 |
| 85730 |
|
32 |
26 |
$77.59 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
17 |
14 |
$62.14 |
| 85610 |
|
33 |
27 |
$59.67 |
| 82607 |
|
38 |
28 |
$36.10 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,407 |
1,987 |
$15.82 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
13 |
12 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
14 |
12 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
19 |
14 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
660 |
552 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,130 |
940 |
$0.00 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
698 |
534 |
$0.00 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
88 |
54 |
$0.00 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
15 |
12 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
33 |
24 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
15 |
12 |
$0.00 |